AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03548922 — intervention group
Intervention type: OTHER
Intervention: Tanner stage
Description: a scale of pubertal development in children, adolescents
Study NCT03548922 — intervention group
Intervention type: OTHER
Intervention: Risser stage
Description: a measure showing the growth left in the spine
Study NCT03548922 — intervention group
Intervention type: OTHER
Intervention: Pressure of correction
Description: an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
Study NCT03548922 — intervention group
Intervention type: OTHER
Intervention: Pectus carinatum protrusion
Description: distance from the point of maximum protrusion to the estimated normal level of chest wall
Study NCT01582555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline nasal irrigation alone
Description: control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
Study NCT01092624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study NCT01092624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study NCT01092624 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study NCT01582555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dissolved N-Acetylcystine
Description: intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
Study NCT01627093 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records
Study NCT01627093 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01092624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study NCT00741273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsule, single dose
Study NCT02036060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
Description: Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
Study NCT02036060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel 75 mg/m2 + prednisone 10 mg/d
Description: Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
Study NCT03005288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338 10 mg/kg
Description: intravenous infusion every four weeks
Study NCT03005288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion every four weeks
Study NCT02393261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2500ml Huaren peritoneal dialysate
Description: use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
Study NCT02393261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2000ml peritoneal dialysate
Description: use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
Study NCT03020355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placental Blood Drainage
Description: Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
Study NCT03020355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: not Placental Blood Drainage
Description: In the control group, the clamped cord will not released.
Study NCT01983345 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prenatal surgical repair of fetal myelomeningocele
Description: open surgical repair of myelomeningocele before 26 weeks gestational age
Study NCT04319289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic interval training and Vitamin D supplementation,
Description: The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day .
Study NCT04993118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition technique
Description: Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session
Study NCT04993118 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Compression,Hotpack,TENS
Description: Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
Study NCT02237079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogens (BZA/CE)
Description: Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
Study NCT02237079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Daily placebo tablet
Study NCT01077661 — intervention group
Intervention type: DRUG
Intervention: Nebivolol
Description: patients administrated Nebivolol according to the prescribing information
Study NCT00771628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flex-It Stylet
Description: Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
Study NCT00771628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard malleable stylet
Description: Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
Study NCT04319289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation only
Description: One capsule containing (cholecalciferol 400 IU) was taken every day .
Study NCT04319289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic interval training only
Description: The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks
Study NCT02583698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT02583698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02670785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Capsule (EVC)
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Study NCT02670785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Study NCT01156415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178
Study NCT03717194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Description: Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
Study NCT03717194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
Study NCT02320071 — intervention group
Intervention type: OTHER
Intervention: Examination of abdominal wall strength changes over time
Study NCT01628770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Description: Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
Study NCT01628770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulphate
Description: 200mg twice daily
Study NCT05122858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS guided biliary drainage
Description: A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility will then be confirmed via endoscopic ultrasound (EE) from the duodenal bulb and via Doppler ultrasound to exclude any disturbing vessels. In order to maintain the stability of the duodenal bulb, the long endoscope position will be used whenever possible. A SMAL (AxiosTM) will be inserted with the assistance of cautery and then deployed. The use of a guidewire and the choice of stent size will be at the endoscopist's discretion.
Study NCT05122858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: A duodenoscope is advanced to the papilla orally. The bile duct is then cannulated with a sphincterotome using the guidewire assisted technique. A cholangiogram is then performed followed by the placement of a self-expanding metallic bile stent. The performance of the biliary sphincterotomy before placement of the stent and the choice of the size of the stent will be at the discretion of the endoscopist.
Study NCT01875887 — intervention group
Intervention type: PROCEDURE
Intervention: rapid prototyping technology
Description: Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
Study NCT04055233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polihexanide; Serasept
Description: Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.
Study NCT04055233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl; saline
Description: Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.
Study NCT01320722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D ergocalciferol
Description: 50,000 unit soft gel capsule once per week for 8 weeks
Study NCT01320722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
Study NCT01320722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
Study NCT01320722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soft gel once per week for 8 weeks
Study NCT01320722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
Study NCT03588260 — intervention group
Intervention type: OTHER
Intervention: no intervention - cross-sectional observational only
Description: no intervention - cross-sectional observational only
Study NCT04614857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclined treadmill gait
Description: All subjects underwent measurements of muscle activity and respiratory metabolism energy during treadmill walking at a comfortable speed for 5 minutes and measured by three conditions (#0% inclined treadmill gait, #10% inclined treadmill gait, and #16% inclined treadmill gait)
Study NCT02451644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Description: patient will cary pedometer
Study NCT00943423 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Field Radiotherapy
Description: IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
Study NCT00943423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No further treatment
Study NCT03004599 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System
Description: Transcatheter Aortic Valve Implantation via Transfemoral Approach
Study NCT01543685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 40 mg TID capsules
Study NCT01543685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 40 mg BID capsules
Study NCT01543685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 20 mg TID capsules
Study NCT01543685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 200 mg capsules
Study NCT01543685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT02015351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
Study NCT03645616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Description: First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires.
Study NCT03645616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 10 meters walk test
Description: First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test.
Study NCT00365417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
Study NCT00365417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m\^2 IV every 21 days x 4 cycles
Study NCT00365417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 IV every 21 days x 4 cycles
Study NCT00365417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Following clinical response assessment, 650 mg/m\^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
Study NCT03645616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 30 Second Sit to Stand Test
Description: At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.